Press Releases Revvity, Inc.

Equities

RVTY

US7140461093

Market Closed - Nyse Other stock markets 01:30:01 04/05/2024 am IST			5-day change	1st Jan Change
100.6 ^USD	-0.46%		-0.89%	-7.96%

30/04	TD Cowen Adjusts Price Target on Revvity to $130 From $123	MT
30/04	JPMorgan Adjusts Price Target on Revvity to $105 From $100, Neutral Rating Maintained	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Revvity : Q1 2024 Earnings Transcript	30/04	PU
Revvity: Q1 Earnings Snapshot	29/04	AQ
Revvity Announces Financial Results for the First Quarter of 2024	29/04	BU
Revvity Board Declares Quarterly Dividend	26/04	BU
Revvity’s EUROIMMUN and ALPCO-GeneProof Announce Strategic Partnership to Expand CE-IVD Molecular Assay Offerings	25/04	AQ
Revvity to Present at BofA Securities 2024 Health Care Conference	25/04	BU
Revvity Unveils a New Era of Automated Tuberculosis Testing	24/04	BU
Revvity Signals Software's New Synergy Solution Redefines Collaboration between Pharma and Contract Partners	16/04	AQ
Revvity Signals Software’s New Synergy Solution Redefines Collaboration Between Pharma and Contract Partners	15/04	BU
Revvity To Hold Earnings Call on Monday, April 29, 2024	04/04	BU
Preliminary Injunction Granted to Enforce Revvity s Rights and Cloud Software Group s Obligations Related to Spotfire Software	03/04	AQ
Preliminary Injunction Granted to Enforce Revvity’s Rights and Cloud Software Group’s Obligations Related to Spotfire Software	02/04	BU
Revvity Files Complaint and Seeks Injunctive Relief Against Cloud Software Group	21/03	BU
Revvity Signals Software Introduces Signals ChemDraw Offering to Set New Standard for Cloud-Native Chemistry Communication	18/03	BU
Revvity : Notice of Annual Meeting and Proxy Statement 2024	13/03	PU
Revvity to Present at Upcoming Investor Conferences	21/02	BU
Revvity Signals Software Unveils Signals Clinical Solution to Accelerate Critical Clinical Trial Insights and Data-Driven Decisions	13/02	BU
Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2023	01/02	BU
Revvity Elects Sophie Vandebroek and Michael Klobuchar to its Board of Directors	26/01	BU
Revvity Board Declares Quarterly Dividend	26/01	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Revvity, Inc.

Equities

RVTY

US7140461093

Press Releases

Filters